Chromocell Therapeutics Co. (NYSE:CHRO – Get Free Report)’s share price traded down 15.1% during trading on Friday . The stock traded as low as $0.58 and last traded at $0.59. 153,515 shares were traded during trading, an increase of 130% from the average session volume of 66,810 shares. The stock had previously closed at $0.69.
Chromocell Therapeutics Price Performance
The stock’s fifty day moving average is $0.65 and its two-hundred day moving average is $0.92.
Chromocell Therapeutics Company Profile
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.
See Also
- Five stocks we like better than Chromocell Therapeutics
- Top Stocks Investing in 5G Technology
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- How Technical Indicators Can Help You Find Oversold Stocks
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Ride Out The Recession With These Dividend Kings
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Chromocell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromocell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
